mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary. - Wikidata - awgldk - TriplyDB

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

http://www.wikidata.org/entity/Q37346570

about

Clear cell carcinoma of the ovary: molecular insights and future therapeutic perspectives Potential targets for ovarian clear cell carcinoma: a review of updates and future perspectives The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges Clear cell carcinoma of the ovary: is there a role of histology-specific treatment?Mammalian target of rapamycin is a therapeutic target for murine ovarian endometrioid adenocarcinomas with dysregulated Wnt/β-catenin and PTEN Efficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer Rapamycin synergizes cisplatin sensitivity in basal-like breast cancer cells through up-regulation of p73.Investigational agents in development for the treatment of ovarian cancer NVP-BEZ235, a dual PI3K/mTOR inhibitor synergistically potentiates the antitumor effects of cisplatin in bladder cancer cells.Estrogen signaling crosstalk: Implications for endocrine resistance in ovarian cancer.Vascular endothelial growth factor is a promising therapeutic target for the treatment of clear cell carcinoma of the ovary.The target therapy of ovarian clear cell carcinoma.Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro.Multiple genetic alterations within the PI3K pathway are responsible for AKT activation in patients with ovarian carcinoma Activation of mammalian target of rapamycin (mTOR) in triple negative feline mammary carcinomas.Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma.Growth differentiation factor 15 stimulates rapamycin-sensitive ovarian cancer cell growth and invasion.Preclinical Efficacy for AKT Targeting in Clear Cell Carcinoma of the Ovary Targeting miR-381-NEFL axis sensitizes glioblastoma cells to temozolomide by regulating stemness factors and multidrug resistance factors Ovarian cancer: opportunity for targeted therapy.Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group study.Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.Vascular endothelial growth factor A as predictive marker for mTOR inhibition in relapsing high-grade serous ovarian cancer Triple-negative breast cancer: are we making headway at least?Thioridazine induces apoptosis by targeting the PI3K/Akt/mTOR pathway in cervical and endometrial cancer cells Crosstalk between PI3K and Ras pathways via protein phosphatase 2A in human ovarian clear cell carcinoma Suppression of the GTPase-activating protein RGS10 increases Rheb-GTP and mTOR signaling in ovarian cancer cells.Molecular Mechanisms of Trastuzumab-Based Treatment in HER2-Overexpressing Breast Cancer Current status and implications of microRNAs in ovarian cancer diagnosis and therapy.New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.Targeting signaling pathways in epithelial ovarian cancer.New developments in the treatment of HER2-positive breast cancer Candidate microRNA biomarkers in human epithelial ovarian cancer: systematic review profiling studies and experimental validation.ARID1A mutations and PI3K/AKT pathway alterations in endometriosis and endometriosis-associated ovarian carcinomas.Potential role of mTORC2 as a therapeutic target in clear cell carcinoma of the ovary.A Review of mTOR Pathway Inhibitors in Gynecologic Cancer Molecular pathogenesis of ovarian clear cell carcinoma.An overview of tyrosine kinase inhibitors for the treatment of epithelial ovarian cancer.

P2860

Q26749280-4ABCADA3-DA70-40EA-84FB-BED148FFD8C6 Q26775315-BAB8E503-EEB8-4A9D-B0AB-23CFA390D489 Q26851852-C0163553-1A5D-42CC-A7FD-6A820989AED5 Q27012348-A8EE2862-67EF-4227-B6A0-BEC87516ECB8 Q27335766-2C2F79C3-46EA-4139-BC89-F015EC6E48F9 Q30313117-5DFE7CBF-9A4C-4B12-8996-F8D414544D7F Q33634277-1580FD26-1751-49A2-B102-0C9F09E560D9 Q33649918-D9319EDE-E32B-4A79-99D4-9DC905DEE44F Q33920800-37FD0A28-564E-42F4-82FE-7653A29F86BD Q34000632-DBDAF9E0-50E6-42FF-8522-564D2B14A104 Q34022694-630578BD-41D3-4E62-92B5-88C808D60A47 Q34139923-125E2148-4FFE-4E8F-A2DE-1316504623F9 Q34274069-6B7286B7-C5E9-4F87-A08F-0874D18952F5 Q34452761-2494A764-4DBE-4AD4-93B3-D70EC7268937 Q34586019-4FFE24AA-22D2-46EA-BB1B-E18BAF5171DF Q34669344-067823AA-D551-4645-8A1F-968EB91C9291 Q34810176-CA7FA04F-2F0C-4991-A067-6F66263A24B4 Q35087191-69FF2C0B-40BC-4306-8921-14DA330CCB51 Q35434007-9F020367-78B3-4969-BAA0-05E40EFF2D87 Q35545648-F3EF7440-1A7B-4BAC-ADCE-455B64970AF1 Q35659945-04280D2C-FC85-4C4D-8922-8AEC5B307DDD Q35723911-C3DB9F31-25E2-41FF-A6BF-80C7626E9A27 Q35913613-3D528685-CF27-45F6-BDEF-BAC5B7B887BF Q35960779-55663398-C8B4-4C0F-8AB1-42449F5ABA50 Q35992948-DA2EA987-06BB-45BF-921B-D97E624148C8 Q36061177-FF0CC4D8-E1E0-4A60-81BE-CF723FCE775B Q36147137-BF89AC56-7C42-4F7D-9F8C-16C783667A91 Q36212745-DA149AD4-A63C-4644-9FCC-FD9C7602DFEF Q36302314-F8CBD9CF-BE51-4E7E-B8F8-5563B6E1BFB1 Q36440214-8ECC0F1F-BFC1-4336-9DF8-EB7ADB0510E5 Q36517492-935F78A3-C754-494A-8B27-EF71BC1AE5BD Q36889642-B34AFCF8-1030-484E-BF71-D9F8E1BE5492 Q36913614-000081CC-35BB-4CE3-963C-E756CDFC3A10 Q37016382-8BB369E7-ECFC-4B1C-882C-4424C4FB5964 Q37152727-55579048-0588-4A7F-ADF6-A13D39255BDD Q37225222-C04B75D2-8D54-4FD8-A0C9-7D927E33328A Q37367848-02FFC924-124E-484F-803C-8A820118B194 Q37668889-1DCCB001-B260-4260-AA55-B64B0D7CF013 Q38465850-D632E061-8DBA-4377-A0E9-D433A760E49B Q38631373-B96AA52C-D901-458F-BBE2-692A8FC8D990

P2860

mTOR is a promising therapeutic target both in cisplatin-sensitive and cisplatin-resistant clear cell carcinoma of the ovary.

http://www.wikidata.org/entity/Q37346570

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 August 2009

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@en

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@nl

type

label

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@en

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@nl

prefLabel

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@en

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@nl

P1433

Q37346570-1E945508-5CF9-405A-ACD5-1E0DD6D2E138

P1476

Q37346570-28E45FE4-786B-4F2F-83B8-9032AE55BB9F

P2093

Q37346570-08D5F089-BC51-4A22-BB67-6C7D99F4D634

Q37346570-186D14C7-9EAC-427D-A735-4AE8FD10C15D

Q37346570-18F1E626-ED75-4969-8433-C8161A11DC69

Q37346570-2F847731-599E-4C0D-AC96-E02248132DF2

Q37346570-3E21F0FD-CA7E-4287-8114-7DCFFB60F008

Q37346570-46F6CC13-D809-42E1-B97D-2EA3311D3DCB

Q37346570-851AFE42-21A9-465C-9E11-5B6B23A0129C

Q37346570-8B14D934-5395-43F9-9735-9EBFDC804F15

Q37346570-9D72DB67-AECA-4D70-97F2-26FEBBA441CF

Q37346570-AD0D90E4-F2B7-4341-8186-7AF41A4562A7

P2860

Q37346570-06E54DAB-AF99-4C6F-9F25-6AFD62F5A5D1

Q37346570-07CAC4B3-207E-4D4C-85B5-2D393D311754

Q37346570-08511504-E7E3-4872-8520-CAB626DEDF95

Q37346570-116F4087-8408-4E6E-8BAF-89AF5397AD07

Q37346570-14B77DB7-531B-49D1-85AF-6ED336CD8C54

Q37346570-18DAF255-4B0F-4B6A-AFA8-7DB73D950270

Q37346570-222F1307-DEF9-4184-89C5-F358740009C4

Q37346570-2F49AC73-6C1A-4B34-946C-5B46409D59B9

Q37346570-3CFD0E0C-F38C-4B78-AF00-3243F0433D05

Q37346570-402AB641-8B39-42E2-8877-23667CD78C52

P304

Q37346570-F088321C-B407-4048-A946-9F77CFB0E8A6

P31

Q37346570-8C48975E-E960-4A65-9273-521EBA66620A

P356

Q37346570-21BFA4B1-B45D-403B-B066-2DD5C11C42CC

P407

Q37346570-60B1A93D-7774-429E-A69D-069449C06047

P433

Q37346570-984F4D98-BF3E-48C8-AF35-B819FB0A75FE

P478

Q37346570-99A75C63-F5A4-42A7-A35B-86669F055ED7

P577

Q37346570-3292B1A7-45F2-439C-95E1-0B235C75392B

P698

Q37346570-CB63E6E6-99E0-4389-8530-5A223F93817A

P932

Q37346570-631A5E25-BC3A-4B00-BDA0-8476A1E5DC0F

P356

1078-0432.CCR-09-0365

P1433

Clinical Cancer Research

P1476

mTOR is a promising therapeuti ...... r cell carcinoma of the ovary.

@en

P2093

Andres J Klein-Szanto

http://www.w3.org/2001/XMLSchema#string

Chiaki Kawase

http://www.w3.org/2001/XMLSchema#string

Deborah A Altomare

http://www.w3.org/2001/XMLSchema#string

Joseph R Testa

http://www.w3.org/2001/XMLSchema#string

Kenichirou Morishige

http://www.w3.org/2001/XMLSchema#string

Kenjiro Sawada

http://www.w3.org/2001/XMLSchema#string

Mareo Yamoto

http://www.w3.org/2001/XMLSchema#string

Masahide Ohmichi

http://www.w3.org/2001/XMLSchema#string

Masahiko Tsujimoto

http://www.w3.org/2001/XMLSchema#string

Masami Hayashi

http://www.w3.org/2001/XMLSchema#string

P2860

Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR.

Cancer statistics, 2008

TOR, a central controller of cell growth.

Sustained activation of the JNK cascade and rapamycin-induced apoptosis are suppressed by p53/p21(Cip1)

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study.

Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Activation of Akt and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition.

P304

5404-5413

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/1078-0432.CCR-09-0365

http://www.w3.org/2001/XMLSchema#string

P407

P433

17

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2009-08-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19690197

http://www.w3.org/2001/XMLSchema#string

P932

2743856

http://www.w3.org/2001/XMLSchema#string